GHRP-2 and Cysteamine reverse growth retardation in yaks by boosting GH, IGF-1, and muscle protein deposition via distinct pathways
Background
Growth retardation in livestock like yaks poses a significant economic challenge, often linked to deficiencies in the somatotropic axis, which regulates growth through hormones like Growth Hormone (GH) and Insulin-Like Growth Factor 1 (IGF-1). The abstract establishes a significant positive correlation between body weight and serum levels of GHRH (P < 0.05, R = 0.45), GH (P < 0.05, R = 0.47), and IGF-1 (P < 0.05, R = 0.62) in lighter yaks, suggesting that insufficient hormone secretion is a primary cause of stunting. This study investigates two potential interventions: GHRP-2, a synthetic peptide known to stimulate GH release, and Cysteamine (CS), a compound that can inhibit the GH-suppressing hormone Somatostatin (SS), to see if they can correct this hormonal deficit and restore normal growth performance.
Study Design
Researchers selected fifteen 1-year-old Qinghai high plateau yaks with growth retardation (avg. weight 54.8 ± 8.24 kg). They were randomly assigned to three groups (n=5 each): a negative control (NG), a GHRP-2 injection group (GG), and a cysteamine feeding group (CG). Two additional control groups were used: a positive control group (PG) of five yaks with normal growth performance (avg. weight 75.3 ± 2.43 kg) and a baseline cohort of thirty-six yaks for initial correlation analysis. Endpoints included average daily gain (ADG), serum hormone levels, myofiber size, and mRNA expression of key genes in the liver and skeletal muscle, analyzed via methods like qPCR.
Results
Both interventions significantly improved growth. The average daily gain (ADG) in the GHRP-2 (GG) and Cysteamine (CG) groups was significantly higher than in both the normal-growth positive control (PG) and growth-retarded negative control (NG) groups (P < 0.05). Both treatments also significantly increased myofiber diameter and area (P < 0.05). Mechanistically, they differed: GHRP-2 significantly elevated serum GH and IGF-1 levels (P < 0.05) and upregulated the mRNA expression of GHR, IGF-1, and IGF-1R in liver and muscle. > It also enhanced the expression of key muscle synthesis genes PI3K, AKt, and mTOR in skeletal muscle (P < 0.05). Conversely, Cysteamine significantly reduced serum somatostatin (SS) levels and hypothalamic SS mRNA expression (P < 0.05). It primarily worked by decreasing the mRNA expression of muscle atrophy genes Atrogin-1 and MuRF1 (P < 0.05), indicating an anti-catabolic effect.
Key Findings
- GHRP-2 and Cysteamine significantly increased average daily gain (ADG) over both normal and growth-retarded control yaks (P < 0.05).
- GHRP-2 significantly enhanced serum GH and IGF-1 levels (P < 0.05) and upregulated the PI3K/Akt/mTOR muscle protein synthesis pathway (P < 0.05).
- Cysteamine significantly reduced serum Somatostatin (SS) levels (P < 0.05) and downregulated muscle atrophy genes Atrogin-1 and MuRF1 (P < 0.05).
- Both treatments significantly increased the myofiber diameter and area of skeletal muscle (P < 0.05).
- In growth-retarded yaks, body weight was significantly correlated with serum GH (R = 0.47) and IGF-1 (R = 0.62) levels (P < 0.05).
Why It Matters
The study demonstrates two distinct and effective pharmacological pathways to combat growth retardation caused by somatotropic axis deficiency. For users of growth hormone secretagogues, this provides evidence that GHRP-2's muscle-building effects are directly mediated by upregulating the anabolic PI3K/Akt/mTOR pathway, not just by increasing GH and IGF-1 levels. The findings on Cysteamine highlight a different, anti-catabolic approach by inhibiting somatostatin and reducing ubiquitin-proteasome pathway activity. This suggests a potential synergistic effect where combining a GH-releasing peptide with a somatostatin inhibitor could simultaneously boost protein synthesis and block protein breakdown, potentially leading to more robust growth and recovery. While this is an animal study in yaks, the conserved nature of these hormonal axes provides a strong preclinical model for similar conditions in other mammals.
